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Summary: The protein pättern of cerebrospinal fluid (CSF) of 334 patients with various neurological and
systemic diseases was investigated by high resolution two-dimensional electrophoresis (2-DE). 2-DE gels of
normal CSF contain piroteins which are not detectable in 2-DE gels of serum. Disturbances of the blood-
brain or blood^CSF barrier, and degenerative diseases of the brain and malignant diseases produce specific
changes on 2-DE gels of the CSF. The appearance of 10 spot areas in the light chain region of 2-DE gels
seem to be connected with the diagnosis of multiple sclerosis. The sensitivity and the specificity of these spot
areas for the diagnosis of multiple jsclerosis are described. Proteins within the ten spot areas are immunoglobu-
lin light chains or sübstances which cross-react very strongly with light chain antibodies äs demonstrated by
immunoblottiiig and iIilm^nöäbso tion.
but at a concentration one two-hundredth of that in
Cerebrospinal fluid (CSF) is in close contact with the serum. Two-dimensional electrophoresis (2-DE) of
brain, and some proteins in CSF are derived from serum and CSF protein$ has demonstrated that cer-
the central nervous System (CNS) (1). Many serum tain proteins are normally present in only one of the
proteins are present in CSF of healthy individuals, two fluids (2-9). Diseases involving the CNS may
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markedly affect the protein pattern of the CSR Such
changes, c.g. multiple sclerosis (1) or disorders of
the blood-brain barrier (10) are used diagnostically.
Malignant and infectious diseases may also alter CSF
protein concentrations and patterns.
High resolution 2-DE in polyacrylamide gels (PAGE),
äs described originally by O'Farrell (11) and later
adapted for serum by Anderson & Anderson (12), is
a very powerfull technique for resolving proteins in
biological fluids, particularly when it is combined
with a silver staining procedure (13). This method
has been adapted for CSF by Merril et al. (14) and
we have used a modification of the Anderson proce-
dure (1).
Materials and Methods
Patients and cerebrospinal fluid
Three hundred and thirty four CSF specimens were collected
from patients from, 3 to 87 years of age who underwent diag-
nostic spinal taps and spinal myelograms at the Mayo Clinic.
Approximately equal numbers of the sexes were represented.
CSF specimens were received in the laboratory within one hour
after spinal tap. Specimens were centrifuged to remove cellular
elements and stored at -70 °C until analysed by 2-DE.
Clinical analysis and the laboratory procedure were carried out
independently.
Sixteen patients who had no evidence of any organic neurologi-
cal or systemic diseases such äs vascular or tension headache,
idiopathic scoliosis, tension myalgia, or atypical facial pain,
were used äs the control group. Other patients were divided
into 13 disease groups (tab. 1).
Tabl. 1. Clinical diagnosis of patients.
16
58
Control
Demyelinating disease
Definitive multiple sclerosis 14
Probable multiple sclerosis 14
Possible multiple sclerosis 21
Others ,
 f 9
Peripheral neuropathies 16
Polyradiculopathies 23
Disc syndromes, spinal Stenosis etc. 21
Myeiopathies 15
CNS degenerative diseases, including dementia 31
Encephalopathies 11
Seizures 8
Meningoencephalitis . 28
Hydrocephalus 9
CNS neoplasms 26
Systemic malignancies without CNS 22
involvement
Miscellaneous including syphilis and 50
post operative
Total 334
The second dimension, SDS-PAGE in a 100 g/l to 230 g/l
acrylamide gradient slab gel, was performed in DALT tanks
(Electro/Nucleonics, Inc., Oak Ridge, TN, USA) with a buffer
containing 3.5 mmol/1 SDS, 24 mmol/1 tris, 0.2 mol/1 glycine.
2-DE gels were stained with ammoniacal silver nitrate and
formaldehyde citrate (15, 16). Stained 2-DE gels were photo-
graphed and inspected and evalüated visually. Spots on the 2-
DE gels of CSF were identified by comparison with a reference
map of normal human serum (15). The reproducibility of 2-
DE has been described previously (15).
Specimen preparation
Specimens containing 300 § of protein (deterrained turbidimet-
rically on the aca III (Du Pont, Inc., Wilmington, DE, USA)
were dialysed against 0.1 mol/1 ammonium formate and concen-
trated by lyophilization. In prelirainary experiments we found
that with this procedure at least 96% of the starting protein
quantity was recovered. Protein was dissociated by heating for
5 min at 95 °C in 100 sample preparation buffer, pH 9.5,
containing 20 g/l sodium dodecylsulphate (SDS), 50 g/l mercap-
toethanol, 50 mmol/1 cyclohexylamino sulphonic acid (CHES,
Calbiochem, San Diego, CA, USA), and 100 g/l glycerol. Ten
samples of this preparation were loaded in duplicate on ISO-
gels.
Electrophoresis
2-DE was performed by a modification of the 1SO-DALT
System of Anderson & Anderson (12) äs described previously
(2, 15). The ßrst or ISO-dimension is isoelectric focusing in
polyacrylamide (35 g/l) under denaturing conditions: 9mol
urea, 20 g surfactant NP-40, 19 g 3.5-10 ampholytes, and 5 g
5-7 ampholytes (Ampholines, LKB Instruments, Rockville,
MD, USA), 1.6g arginine and 1.0g lysine were added to 11
of acrylamide solution. Isoelectric focusing was performed.at
10600 Vh after prefocusing for l h at 200V with 0.85 g/l
phosphoric acid äs anolyte and 1.0 mol/1 sodium hydroxide äs
catholyte. ISO-gels were equilibrated subsequently in a buffer
containing 20 g/l SDS for 8 min and quickly frozen in a solid
CO2/ethanol bath.
Immunoabsorption
Antibodies against the human kappa and lambda light chains
(Dakopatts, Accurate Chemical & Scientific Corporation,
Westbury, NY, USA) were coupled to CNBr-activated Sepha-
rose 4B (Pharmacia, Piscataway, NJ, USA) following the proce-
dure described by the manufacturer and Dermer et äl. (4).
Antibody protein (2 mg) was coupled to l ml gel at 4 °C and
incubated overnight in a buffer at pH 8.3 containing 0.1 mol/1
sodium bicarbonate and 0.5 mol/1 sodium chloride. Free ligands
were blocked with l mol/1 ethanolamine at pH 8.0 and excess
protein was washed off with 0.1 mol/1 aeetate buffer containing
0.5 mol/1 sodium chloride and 2 g/l detergent Tween 20. Antibö-
dy-coupled Sepharose was equilibrated and stored in phos-
phate-buffered saline pH 7.2 with 10 mg/1 sodium azide.
Immunoabsorption was performed in microcolumns (3 ml dis-
posable syringes) filled with l ml Sepharose coupled to the
individual antibody. Three CSF and three human serum speci-
mens, each containing 350 g protein were first absorbed on
the anti-kappa antibody colurrm, and in a second Step the
eluent was absorbed on the anti-lambda antibody colümn. The
specimen, from which light chains had been depleted, was
treated in the same way äs the original CSF specimen (foliowing
dialysis and lyophilization) and subjected to 2-DE. Bound light
chains were eluted in two steps; first with an acid glycine bufier
(0.1 mol/1 glyeine and 0.5 mol/1 sodium chloride adjusted to
pH 2.5 with 0.2 mol/1 hydrochloric acid), then elution was
repeated with 100 ml/l dioxane in the same buffer. The pH of
the eluate was immediately raised by addition of solid tris. The
eluate was treated in the same way äs the absorbed samples.
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Blot t ing and immun o staining
Protein was transfered from the SDS-Polyacrylamide gel onto
a nitrocellulose sheet (Schleicher & Schuell, Inc., Keene, NH,
USA) in a Trans Blot Cell (Bio-Rad Laboratories, Richmond,
CA, USA) according to Symmgton (17). The transfer bufier
consisted of 25 ramol/1 tris, 192 mmol/1 glycine and 200 ml/l
melhanoi at pH 8.3. The blotting was performed at 150 V for
3 h with cooling; nitrocelhilose sheets were removed from the
SDS-polyacrylamide gel and blocked in 30 g/l gelatin for l h
in tris-buffered saline at pH 7.5 (20 mmol/1 tris and 0.5 mol/1
sodiura Chloride). Then the sheets were incubated for 90 min
in a first antibody solution at a concentration of l: 500. Anti-
bodies were raised in rabbits (Dakopatts, Accurate Chemical &
Scientific Corporation, Westbury, NY, USA). After washing
the nitrocellulose sheets in tris-buffered saline (four times for
20 min at room temperature), they were incubated with a
second anli-rabbit antibody coupled with horseradish peroxi-
dase (Bio-Rad Laboratories, Richmond, CA, USA) at a con-
centration of l : 1500. Again the sheets were washed extensively
in tris-buffered saline, and specific proteins were visualized by
addition of 4-chloro-naphthol and hydrogen peroxide.
between these spots and any diseases, but the proteins
in this area seem to be more prominent in inflamma-
tory states. The light chains in CSF differ from those
in serum äs exemplified by spots 12—17 in figure 1.
The difference in spot 15 is characteristic for 2-DE
gels of CSF and is not apparent in other biological
fhiids (amniotic fluid, urine, saliva, pleural and ab-
dominal effusions) that we have studied.
The relative amount of transthyretin (area 11 in fig.
1) is increased in CSF compared with serum. The
cathodic end of transferrin (area 4 in fig. 1) is more
basic in CSF than in serum. Also, the heavy chains
of IgG (gamma chains in fig. 1) in CSF differ from
those iri serum with the basic end of the chain being
less pronounced. The electrical charges of the gamma
heavy chain subunits are somewhat different.
Results
The most obvious differences between 2-DE gels of
proteins from serum and CSF are apparent in figure
l. The protein pattern of-both specimens are compar-
able when CSF is concentrated approximately 100 to
200 fold. The spots visible within area 8 (fig. 1) are
present in most CSF specimens but are abseilt from
serum. This area includes apolipoprotein E and sev-
eral other sets of spots with different charges and
molecular mass. Nö clear relation could be found
Changes associated with pathological states
Patients in whom we suspected disturbance of the
blood-brain or blood-CSF barrier demonstrated a
relative increase in serum-derived proteins in their
CSF compared with the CSF from healthy indivi-
duals. Such proteins are usually present in small
amounts in the CSF of normal individuals. Some
proteins, such äs the beta chain of haptoglobulin and
arantichymotrypsin, are less concentrated in CSF
than in serum. The patterns of subunits of the light
chains are different in CSF and serum (fig. 2).
Mr
82000
77000
67000
55000
43000
25000
17000
Fig. 1. Comparison of 2-DE gels of (A) serum from a healthy control person, (B) CSF from a patient with atypical facial pain.
Spots characteristic of CSF proteins are marked 1 — 17.
4 = basic end of transferrin,
11 = transthyretin,
12—17 = spots within light chain area, (alb = albumin, gam = heavy chains of IgG).
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Some patients with malignant diseases and neurologi-
cal Symptoms, suggesting involvement of the CNS,
demonstrated several characteristic protein spots on
their 2-DE gels (fig. 3). Many of these are present in
the area at the acidic end of the light chains, particu-
larly in patients with leukaemia involving the CNS.
A series of three to four spots of relative molecular
wight of approximately 60000 and an isoelectric
point of approximately pH 7.0 have been observed
on 2-DE gels of CSF from 3 patients with leukaemia
without involvement of CNS. None of the patients
had been treated with intrathecal cytostatic agents.
Patients with multiple sclerosis showed characteristic
protein patterns in the light chains with söme äug-
mentation of other spots normally present in this
region. These included distinctive, sharply edged
spots (fig. 4). We selected ten different locatiöns
within this area on 2-DE gels of CSF from patients
with different degrees of severity of multiple sclerosis
for the evaluation of the relationship of the spots to
the disease äs indicated in figure 4. Some of these
spots are present in 2-DE gels from patients with
other diseases, but to a lesser extent. In table 2 the
distribution and frequency of these spots are listecL
All spots which are classified äs have cleaf ly defined
edges and are distinct. indicates that an area con-
tains a protein Spot with a less defined edge (diffuse
spots). — indicates that no protein is visible within
a spot areä. Spots within areas 6, 7, 8, 9, and 10 (fig.
4) typically have well defined edges. For spots in
these areas the signs + -h, and +, refer to the amount
of protein. The combined frequency of and + +
spots from CSF of patients wiih multiple sclerosis
and other demyelinating diseases was significantly
different (p < 0.01) from CSF from patients withöüt
clinical evidence of demyelinating diseases. We also
calculated the specificity and seasitivity öf each spot
for multiple sclerosis (18). One value was calculated
for sensitivity and specificity fqr spot areas classified
with both and + + and another value for spots
classified with both and + + together with and
+. The true positive rates (sensitivity) were plotted
against the false positive rates (l — specificity), and
receiver operating characteristic (RÖC) curves were
drawn (fig, 5). The detection of a protein within spot
areas with + and + -l- and and reveals a high
Fig. 2. 2-DE gels of (a) CSF of a normal patient, (b) CSF of
a patient with a disc syndrome and (c) serum of a
normal control person. Serum-speeific spots in CSF
which indicate a damaged blood-brain or bloöd-CSF
barrier are marked with arrows and äfe nuinbered 1—9
. (alb = albumin). Note these riuinbers do not corre-
spond to the same numbered spots,' in figure 1.
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Fig. 3. 2-DE of CSF from a patient with acüte lymphatic leukaernia. Spots within the rectangle were found in three other patients
with the same disease. The other marked spots were only found in this specimen.
sensitivity, but low specificity for the diagnösis of
multiple sclerosis; On the other band, the evaluation
of shafp edged spot formation in spot areas 1 — 5
(classified with a) and high concentrations in spot
areas 6—10 (classified with H- +) against spots with
blurred boundary (classified with ß) pr low concen-
trations (classified with +) or absence (classified with
—) improves specificity but diminishes sensitivity.
Spots 6 — 10 showed a positive correlätion with sensi-
tivity and a negative correlation with specificity with
respect to the quantity of protein. Spots within the
areas 1 — 5 demonstrated good specificity for multiple
sclerosis, if their edges are well defined. If these spots
are evaluated depending on their presence only (spots
J. Clin. Chem. Clin. Biochem. / Vol. 25,1987 / No. 2
with well [a] or ill [ß] defined edges) sensitivity in-
creases, but specificity diminishes. Spots within areas
1—4, and 10 show a high specificity but a relatively
low sensitivity for multiple sclerosis. No obvious dif-
ferences in the light chain region could be found
between patients with the different subclasses.
2-DE of CSF from two patients with multiple
sclerosis and from one patient without any obvious
neurological or systemic disease, äs well äs one
human serum, were blotted on nitrocellulose sheets
and stained with peroxidase-labeled antibodies
against the immunoglobulin light chains kappa and
lambda. The nature of the multiple sclerosis-associ-
f
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acidic
Fig. 4. A) 2-DE gel of CSF of a normal control person. The light chain area is marked. Spot äreas 1 — 10 marked with circles
are associated with multiple sclerosis. B) light chain area of 2-DE gel of CSF of a normal control person. C) and D)
light chain areas of 2-DE gels of CSF of patients with multiple sclerosis. E) light chain area of a 2-DE gel of a patient
with encephalomeningitis. F) light chain area of a 2-DE gel of CSF of a patient with Parkinson1* disease. A disease-
associated spot is within the triangle. G) light chain area of a 2-DE gel of a patient with Alzheimer's disease, The spot
apparently associated with Parkinsorfs disease can be recognized in the triangle. The minibering of these spots is not the
same äs in figures l and 2.
0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 OB 0.9 1.0
False positive (1 minus specif icity)
Fig. 5. ROC curves of the 10 spots associated with multiple
sclerosis. Numbers are taken from spot areas äs de-
scribed in figure 4 and table 2. Specificity and sensitivity
relate to the diagnosis of multiple sclerosis. The increase
of specificity and decrease of sensitivity can be recog-
nized if the spot areas are classified only with + + and
a. If only the presence of a protein within the spot areas
(classified äs + and H- 4- äs well äs and ß) is used
for classification there is a high sensitivity, but low
specificity.
ated spots could not cleafly be determined by this
method. Therefore we took CSF specimens from
other patients with the same diagnosis, and depleted
the imimmoglobulin light chains (kappa and lambda)
by immunoabsorption. One CSF specimen of a
patient with multiple sclerosis was absorbed twice
before analysis by 2-DE. Spots 2, 3, and 4 in figure
4 largely disappeared with absorption, although they
were still faintly visible, while the spots l, 5, 6, 7, 8,
9, and 10 of figure 4 disappeared completely. Never-
theless, the strong reaction suggests that the multiple
sclerosis-associated proteins in the light chain region
are immunoglobulin light chains themselves or pro-
teins which show a very high cross-reactivity with
immunoglobulin light chains.
Laboratory data concerning the CSF IgG index (ratio
of IgG and albumin in CSF divided by the ratio of
IgG and albumin in serum) and the presence of
oligoclonal bands (determined by agarose gel electro-
phoresis) were available in only a few cäses. When-
ever the CSF IgG index was increased or oligoclonal
bands were present, the spots associated with multiple
sclerosis were observed on 2-DE gels of CSF within
the light chain area. There was nov' single spot area
J. Clin. Chem. Clin. Biochem. / Vol. 25,1987 / Nö. 2
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that was characteristic of a high index or presence of
oligoclonal bands, and several patients demonstrated
multiple sclerosis-associated spots, although their
CSF IgG index was in the reference ränge and no
oligoclonal bands were present.
A protein Spot described äs specific for Parkinsorfs
disease by Harrington & Menü (7) was also found in
all three patients with this disease whom we investi-
gated (fig. 4F). However, the same spot was also
in the CSF of about one half of the patients with
Alzheimer's disease and other dementias and, to a
much lesser extent, in CSF specimens from patients
with other diseases (fig. 4 E).
Discussion
As our normal control population, we selected CSFs
from patients who showed no evidence of any neuro-
logical or systemic disease, and established a reference
map for 2-DE gels of CSF which has been published
previously (2). This map shows several additional
proteins not present in the map of CSF from normal
individuals published by Goldman et al. (5). However,
it is uncertain whether these differences are related
to the use of different silver stains or to different
control populations.
The protein concentration of CSF is about one two-
hundredth of that in serum. We always loaded ISO-
gels with the same amount of protein to facilitate
Interpretation of gel patterns. The protein concentra-
tions in the CSF specimens varied from 18 mg/1 to
more than 100 mg/1. Therefore different volumes of
CSF were subjected to 2-DE. Upon comparing 2-
DE gels from serum and from concentrated CSF
containing the same amount of protein, we identified
several spots which are present in CSF only. This
does not mean that they are not derived from serum,
because they could be present at a concentration
below the threshold of detection.
Comparison of 2-DE gels of serum and CSF shows
that proteins in spot area 8 (fig. 1) are present in
concentrated CSF but not in serum, but no relation-
ship could be established with any disease state. We
suspect that this group of spots is associated with
inflammatory states affecting the CNS. Spots of area
8 (fig. 1) are similar in appearance to apolipoproteins
on 2-DE gels stained with silver nitrate with the
method described by Oakly (16) and the area overlaps
apolipoprotein E in 2-DE gels of serum (15). This
area consists of at least three different proteins (19).
Spots of area 10 in figure l have been described äs
specific for CSF (6). However, we have observed
these spots in 2-DE gels of pleural and abdominal
effusions and in sera which have been stored over
several years in a freezer with multiple freeze-thaw-
ings (personal observation). The spots may therefore
be related to degradation of larger proteins. Their
presence in CSF may indicate either enhanced degra-
dation of proteins in CSF or slow metabolic elimin-
ation of degraded proteins from the CSF. Addition-
ally these spots reacted with antibocfies against light
chains which suggests an antigenic relationship with
these immunoglobulin subuinits.
Transthyretin (spot 11 in fig. 1), which appears to
contain more aeidic subunits in CSF than in serum
(6), is present normally at a higher concentration in
CSF than in serum. When the serum traüsthyretin is
increased, additional aeidic subunits show up on 2-
DE gels (15).
Andersen & Anderson have demonstrated micro-r
heterogeneity of transferrin in serum due tö neürami-
nidase digestible residues (21). The anodic end of
transferrin, which is much more pronounced in CSF
than in serum, may be due to a diminished amount
of neuraminidase digestible residues since, treatment
of serum with neuraminidase produced a siinilar
transferrin pattern on their 2-DE gels. A conversion
of iron-1 -transferrin to apo-transferrin might also be
a reason for the more basic appearance of transferrin
on 2-DE gels of CSF when compared with 2-DE gels
of serum.
The relative increase of some serum proteins in CSF
in patients with a damaged blood-brain or blood-
CSF barrier suggests that quantitative analysis of
these protein spots might produce further Informa-
tion on the degree of damage. Thus the absolute
amount of protein together with the molecular size
and Charge of specific proteins might be of value in
assessing the extent of damage.
The spots we have found in CSF of patients with
malignancies involving the CNS were not constant
from patient to patient, except for a series of spots
which we found in three patients with acute lymphatic
leukaemia. Each of these spots must be characterized,
and investigated in other patients with leukaemia and
other diseases to establish its diagnostic specificity.
Certain imimmoglobulins have been described äs oli-
goclonal bands in CSF of patients with multiple
sclerosis. They also appear in other inflammatory
processes of the CNS which are usually accompanied
by increased immunoglobulin concentrations in the
CSF. Oligoclonal bands in CSF äre not specific for
multiple sclerosis (1). Changes in the light chain area
and particularly the formation of additional spots
have been noted with 2-DE previously (2, 3, 8, 21).
The density of these areas correlated well with oligo-
clonal band formation (3, 8).
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In this study we decided to characterize spots which
seemed to be associated with multiple sclerosis ac-
cording to their sharp edge and clearly distinguishable
nature (fig. 4, tab. 2). Immunoabsorption and immu-
noblotting demonstrated that these spots were appar-
ently light chains. In one patient with multiple
sclerosis, spot areas 2, 3, and 4 could not be comple-
tely eliminated in the specimen, even after double
absorption before analysis by 2-DE. The reason is
not clear. We postulate that these spots are formed by
immunoglobulin light chains themselves or proteins
which have a high cross-reactivity with immuno-
globulins. Walsh et al. also describe certain spot for-
mation in the light chain area of 2-DE gels of CSF of
patients with multiple sclerosis. They present strong
evidence that they are clonal formations of light
chains (9).
The diagnostic relevance of the light chain area on
2-DE gels from CSF of patients with multiple
sclerosis is of interest. Harrington et al. (8) described
certain areas äs multiple sclerosis-related, and these
appear to be the same äs our multiple sclerosis-
associated areas. Their spot area 118 seems to be
identical to our spot area 2 (fig. 4), their spot area
119 with our spot area 3, their spot area 115
with our spot area 4, and their spot area 114
with our spot area 5. The more basic light chain
spots in our gels are outside the ränge of these investi-
gators' isoelectric protein Separation. By adding basic
amino acids and a highly concentrated catholyte we
achieved better resolution on the basic side of the
gel (15). Additionally, differences in the technique,
reagents and patient selection may give rise to the
differences between their pattern and ours. It is pos-
sible that additionäl spots might be found in the
basic end of the light chain region using a different
isoelectric gradierit for the first dimension. Harrington
et al. (8) describe ari increased density in different
areas, while we found spot formations not only in
these areas but also in öther areas. Multiple sclerosis
is a diagnosis which is mainly established by clinical
characteristics. Biochemical parameters such äs CSF
IgG concentration, CSF IgG index, or oligoclönal
banding do not necessarily concur with the clinical
diagnosis of multiple sclerosis (1). Some patients in
the myelopathy group probably have multiple
sclerosis. The spots were found in the same area in
2-DE gels of CSF of patients with meningoencepha-
litis, but were not usually in a configuration typical
for multiple sclerosis (fig. 4). We classified them äs
+ +, because differentiation is difficult.
The variability of the light chain patterns in 2-DE
gels of patients with multiple sclerosis might indicate
biochemical and immunological variations connected
with this disease. The presence of these spots suggests
that patients with multiple sclerosis may form some
type of atypical immunoglobulins. Many theories ex-
ist about the pathogenesis of multiple sclerosis, in-
cluding direct and indirect virus effects, autoimmune
processes, and deficiencies of the immunoregulatory
System (22). The association of the formation of all
or some of these multiple sclerosis-associated spots
with a pathogenic agent such äs a virus or autoanti-
gen, or with disturbance of the immunoregulatory
System remains to be investigated. The statistical eval-
uation and the ROC curves show that some of these
spots have a high specificity for multiple sclerosis,
but a low sensitivity. The evaluation of the presence
of protein in the spot areas is highly sensitive for
multiple sclerosis, but may not be adequate for the
diagnosis of multiple sclerosis, because high speci-
ficity is also required (23).
Harrington & Merril have described a spot on 2-DE
gels of CSF that is associated with Parkinsorfs disease
(7). We observed this spot in three patients with
this disease, but also in some patients with other
degenerative diseases. The diagnostic specificity of
this protein has still to be investigated.
High resolution 2-DE is a potential tool for investiga-
tion of the protein pattern of CSF. Using various
neurological disorders, we have demonstrated the
potential of this technique for detecting disease-spe-
cific changes in the protein pattern in CSF.
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